Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Autoimmunity reviews 2020-10, Vol.19 (10), p.102634, Article 102634
Hauptverfasser:	Mertz, Philippe, Kleinmann, Jean-François, Lambert, Marc, Puéchal, Xavier, Bonnin, Anthony, Boulon, Carine, Diot, Elisabeth, Hachulla, Eric, Harid, Naoual, Harle, Jean-Robert, Helder, Gil, Kahn, Jean-Emmanuel, Kone-Paut, Isabelle, Lavigne, Christian, Magy-Bertrand, Nadine, Maillard, Helene, Martin, Thierry, Maurier, François, Poindron, Vincent, Schleinitz, Nicolas, Sibilia, Jean, Arnaud, Laurent
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antirheumatic Agents - therapeutic use Biotherapies Female Glucocorticoid-sparing Glucocorticoids Human health and pathology Humans Immunology Infliximab Infliximab - therapeutic use Life Sciences Life Sciences & Biomedicine Male Prospective Studies Risk Assessment Science & Technology Takayasu arteritis Takayasu Arteritis - drug therapy Treatment Outcome Vasculitis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!